Gene-by-Gene will not challenge Myriad in court. The company, one of the first to offer direct to consumer gene tests for BRCA 1/2 stopped its offer in the face of a suit by Myriad seeking to enforce several of its patents -- not previously contested in the original Supreme Court decision last year. Gene-by-Gene now agrees to cease its offer of BRCA gene tests. This may be the first of many similar company decisions as Myriad has sued 4-5 other companies on similar grounds. Gene-by-Gene decided not to spend its time and money in court with Myriad and others are likely to conclude the same. See Patent Docs blog.
Posted by Bruce Lehr Feb 10th 2014.